

PTO/SB/08A (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/783,268
				Filing Date	02/20/04
				First Named Inventor	Savarino, Andrea
				Art Unit	1617
				Examiner Name	To be assigned
				Attorney Docket Number	97728.00147
Sheet	1	of	1		


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers(s), publisher, city and/or country where published.	T <sup>2</sup>
/JS/	1.	SAVARINO, A. et al., The anti-HIV-1 activity of chloroquine. <i>Journal of Clinical Virology</i> , 20:131-135 (2001). Elsevier Science.	
/JS/	2.	SAVARINO, A., et al., Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. <i>Aids</i> , 15:2221-2229 (2001). Lippincott Williams & Wilkins.	
/JS/	3.	SAVARINO, A., et al., Anti-HIV Effects of Chloroquine. <i>Journal of Acquired Immune Deficiency Syndrome</i> , 35(3):223-232 (2004). Lippincott Williams & Wilkins.	
/JS/	4.	SIDHU, A., et al., Chloroquine Resistance in Plasmodium falciparum Malaria Parasites Conferred by pfcrt Mutations. <i>Science</i> , Oct. 4, 298:210-213 (2002).	
/JS/	5.	SAVARINO, A., et al., Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. <i>FASEB</i> , Jan 22, 10.1096/fj.02-0512fje. (2003).	
/JS/	6	MAMMANO, F., et al., Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type I Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug. <i>Journal of Virology</i> , 74(18): 8524-8531 (2000).	
/JS/	7.	NATHOO, S., et al., Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. <i>The Lancet</i> , Sept. 27, 362:1039-1041 (2003).	
/JS/	8.	WARD, SA. Bray, PG., Definitive proof for a role of pfmdr 1 in quinoline resistance in Plasmodium falciparum. <i>Drug Resistance Updates</i> , April, 3(2): 80-81 (2000).	
/JS/	9.	MAKLER, MT, et al., Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. <i>Am J Trop Med Hyg.</i> , Jun; 48(6):739-741 (1993).	

Examiner Signature	/Jagadishwar Samala/	Date (08/14/2007)
--------------------	----------------------	----------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

***Complete if Known***

Application Number	10/783,268
Filing Date	February 20, 2004
First Named Inventor	Andrea Savarino
Art Unit	1617
Examiner Name	WANG, SHENGJUN

Sheet	1	of	2
-------	---	----	---

Attorney Docket Number	97728.00147
------------------------	-------------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code*Number*Kind Code* (if known)				
IJSI	1	WO/92/0145	02/06/1992	Vitetta, et al.		

**Examiner  
Signature**

/Jagadishwar Samala/ 08/11/2007

Date \_\_\_\_\_

08/15/1990

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

**ME5535776**



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
		Application Number	10/783,268
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Filing Date	February 20, 2004
		First Named Inventor	Andrea Savarino
		Art Unit	1617
		Examiner Name	WANG, SHENGJUN
		Attorney Docket Number	97728.00147
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.	T <sup>2</sup>
/JS/	1	Treatment for HIV related Inflammation, Treatment Review, May 1995 (no. 18) Abstract	
/JS/	2	Hydroxychloroquine+ddl+hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles, AIDS Treatment News, December 3, 1990 (No. 332)	
/JS/	3	BOELAET, et al. The Additive In Vitro and Anti-HIV-1 Effect of Chloroquine, When Combined with Zidovudine and Hydroxyurea, Biochemical Pharmacology, 2001, Vol. 61, pages 1531-1535.	
/JS/	4	CHUKWUEMEKA, A Management of HIV-Infected Pregnant Patients in Malaria-Endemic Areas; Therapeutic and Safety Considerations in Concomitant Use of Antiviral and Antimalarial Agents, Clinic Therapeutics, 1999, Vol. 21, No 9, 1999, pages 1456-1496	

Examiner Signature	/Jagadishwar Samala/	Date Considered	08/14/2007
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ME5535776



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>CORRECTED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/783,268
				Filing Date	February 20, 2004
				First Named Inventor	Andrea Savarino
				An Unit	1617
				Examiner Name	Wang, Shengjun
Sheet	2	of	2	Attorney Docket Number	97728.00147

RECEIVED  
CENTRAL FAX CENTER

DEC 06 2006

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.	T <sup>2</sup>
/JS/	1.	Treatment for HIV related inflammation, Treatment Review, May 1995 (no. 18) Abstract	
/JS/	2.	Hydroxychloroquine+ddl+hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles, AIDS Treatment News, December 3, 1990 (No. 332)	
/JS/	3.	BOELAET, et al. The Additive I Vitro and Anti-HIV-1 Effect of Chloroquine When Combined with Zidovudine and Hydroxyurea, Biochemical Pharmacology, 2001; Vol. 61, pages 1531-1535.	
/JS/	4.	CHUKWUEMEKA, A Management of HIV-Infected Pregnant Patients in Malaria-Endemic Areas; Therapeutic and Safety Considerations in Concomitant Use of Antiviral and Antimalarial Agents, Clinic Therapeutics, 1999, Vol. 21, No. 9, 1999, pages 1456-1496	
		/Jagadishwar Samala/ (08/14/2007)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ME16013122.1